Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes?

Diabetes, Obesity and Metabolism

Volumn 15, Issue 11, 2013, Pages 1022-1028

  Nagendran, J ^a   Oudit, G Y ^a   Bakal, J A ^a   Light, P E ^a   Dyck, J R B ^a   Mcalister, F A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular disease; Diabetes mellitus; Sulphonylureas

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM) CHANNEL INHIBITOR; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SULFONYLUREA; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EXPOSURE; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOSPITAL BED CAPACITY; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERTENSION; INCOME; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK ASSESSMENT; SHOCK; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; SULPHONYLUREAS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ALBERTA; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; KATP CHANNELS; LOGISTIC MODELS; MALE; MEDICAL RECORD LINKAGE; MORTALITY; POTASSIUM CHANNEL BLOCKERS; PROGNOSIS; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84885322271     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12126     Document Type: Article

References (23)

1. Nissen SE. Cardiovascular effects of diabetes drugs: emerging from the dark ages. Ann Intern Med 2012; 9: 671-672.
2. Roumie CL, Hung AM, Greevy RA et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 9: 601-610.
3. Jorgensen CH, Gislason GH, Andersson C et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention-a retrospective nationwide cohort study. Cardiovasc Diabetol 2010; 9: 54-62.
4. Lexis CP, Rahel BM, Meeder JG, Zijlstra F, van der Horst IC. The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus. Cardiovasc Diabetol 2009; 8: 41.
5. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 1: 119-124.
6. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004; 53 (Suppl 3): S156-164.
7. Kane GC, Liu XK, Yamada S, Olson TM, Terzic A. Cardiac KATP channels in health and disease. J Mol Cell Cardiol 2005; 6: 937-943.
8. Li RA, Leppo M, Miki T, Seino S, Marban E. Molecular basis of electrocardiographic ST-segment elevation. Circ Res 2000; 10: 837-839.
9. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 5: 1124-1136.
10. Suzuki M, Sasaki N, Miki T et al. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest 2002; 4: 509-516.
11. Lawrence CL, Proks P, Rodrigo GC et al. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia 2001; 8: 1019-1025.
12. Reimann F, Dabrowski M, Jones P, Gribble FM, Ashcroft FM. Analysis of the differential modulation of sulphonylurea block of beta-cell and cardiac ATP-sensitive K+ (K(ATP)) channels by Mg-nucleotides. J Physiol 2003; 547(Pt 1): 159-168.
13. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 11: 1130-1139.
14. Quan H, Li B, Saunders LD. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res 2008; 4: 1424-1441.
15. Donahoe SM, Stewart GC, McCabe CH et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 7: 765-775.
16. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 2: 531-537.
17. Meier JJ, Gallwitz B, Schmidt WE, Mugge A, Nauck MA. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart 2004; 1: 9-12.
18. Zeller M, Danchin N, Simon D, Vahanian et al. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab 2010; 11: 4993-5002.
19. Horsdal HT, Johnsen SP, Sondergaard F, Rungby J. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia 2008; 4: 567-574.
20. Juurlink DN, Gomes T, Shah BR, Mamdani MM. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population. Diabet Med 2012; 12: 1524-1528.
21. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. DIGAMI 2 Investigators. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008; 2: 166-176.
22. Ho ML, Lawrence N, van Walraven C et al. The accuracy of using integrated electronic health care data to identify patients with undiagnosed diabetes mellitus. J Eval Clin Pract 2012; 3: 606-611.
23. Antman EM, Anbe DT, Armstrong PW et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 3: E1-E211.